Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 330

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 330
---
 2 years until April13, 2027. In April 2025 and June 2025, DiamiR amended the convertible note with Kira Sheinerman, one of its founders and the Executive Director, such that the founder loaned DiamiR additional $100,000 and $150,000, respectively. Cyber Attack DiamiR recently discovered a cyber -attackand is still uncovering the full details of it. As of the date hereof, the basis of the attack is believed to be phishing. As DiamiR learns more about the source of the attack and its implications, it will disclose such details in future amendments to this proxy statement/prospectus. Financial Operations Overview Revenue In 2010, DiamiR began the process of developing CogniMIR ®. To date, DiamiR has primarily earned revenue from grants and have not generated any product revenue other than revenues from research testing services for third parties and other revenue generated for performing laboratory services DiamiR previously provided to Interpace Biosciences, Inc. (“Interpace”). DiamiR’s ability to generate product revenue, which it does not expect to occur until at least second half 2025, if ever, will depend heavily on DiamiR’s ability to comply with regulatory requirements for, and to commercialize successfully, CogniMIR ®and other tests in development. Total Operating Expense Total operating costs and expenses consisted primarily of analyzing samples and clinical data associated with revenues from research testing services performed, patent costs and general and administrative costs. 183

Results of Operations Years Ended May 31, 2025 and 2024

| 2025                               
 Statement of Operations Data:      |     | For the Years Ended 
 May 31,             |           | 2024 |     |   |           |   |     | Change |          |   |
|:-----------------------------------|:----|:--------------------|----------:|:-----|:----|:--|----------:|:--|:----|:-------|---------:|:--|
| Grant revenue                      |     | $                   |   531,729 |      |     | $ | 1,319,531 |   |     | $      | (787,802 | ) |
| Other revenue                      |     |                     |   100,000 |      |     |   |         — |   |     |        |  100,000 |   |
| Total revenue                      |     |                     |